

Disclosures

Personal Commercial (6)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
CSL Behring LLC	Other - Research grant to the Institution and financial fees as Steering Committee member of the AEGIS-II study.	Significant (>= \$5,000)	General Cardiology
DalCor Pharma UK Inc.	Other - Research grant to the Institution and financial fees as Steering Committee member for Dal-GenE Study	Significant (>= \$5,000)	General Cardiology
Janssen Pharmaceuticals, Inc	Other - Fees for serving on the Steering Committee for the Librexia AF and ACS studies	Significant (>= \$5,000)	General Cardiology
Merck Sharp & Dohme (New Zealand) Ltd	Other - Research grant to the institution and fees for serving on the Steering Committee	Modest (< \$5,000)	General Cardiology
National Institutes of Health (USA)	Research/Research Grants † Research grants for the ISCHEMIA and MINT Studies	Modest (< \$5,000)	General Cardiology
Sanofi-Aventis Australia Pty Ltd	Other - Research grant to the Institution and financial fees as Steering Committee member of the SCORED and Co-chair running -running of meetings	Significant (>= \$5,000)	General Cardiology

Additional Personal Commercial Disclosures for Education Activities (2)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American Regent	Research/Research Grants † HEART-FID	Significant (>= \$5,000)	General Cardiology
VEVRE	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology

Personal Organizational or Other Non-Commercial (4)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
CSL Behring	Other - Advisory Board	Modest (< \$5,000)	General Cardiology
NHMRC Clinical Trials Centre, the University of Sydney † Chair of the DSMB for the EVIDENCE Study.	Data Safety Monitoring Board	None (\$0)	General Cardiology
SAHMRI	Other - Accommodation support paid to self for attendance at the Clinical trial forum 2023	Modest (< \$5,000)	General Cardiology
VEVRE	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 6/23/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 5/29/2024

Embargo | Signed on 5/29/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 6/23/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.